Identification

Name
Lanreotide
Accession Number
DB06791
Type
Small Molecule
Groups
Approved
Description

Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Its sequence is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2. Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30, 2007.

Structure
Thumb
Synonyms
Not Available
External IDs
BIM-23014C
Product Ingredients
IngredientUNIICASInChI Key
Lanreotide acetateIEU56G3J9CNot AvailableNot applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Somatuline AutogelSolution, gel forming, extended release60 mgSubcutaneousIpsen Biopharm Limited2007-02-22Not applicableCanada
Somatuline AutogelSolution, gel forming, extended release90 mgSubcutaneousIpsen Biopharm Limited2007-02-22Not applicableCanada
Somatuline AutogelSolution, gel forming, extended release120 mgSubcutaneousIpsen Biopharm Limited2007-02-22Not applicableCanada
Somatuline DepotInjection120 mg/.5mLSubcutaneousIpsen Biopharmaceuticals, Inc.2007-11-14Not applicableUs
Somatuline DepotInjection60 mg/.2mLSubcutaneousIpsen Biopharmaceuticals, Inc.2007-11-14Not applicableUs
Somatuline DepotInjection60 mg/.2mLSubcutaneousIpsen Biopharmaceuticals, Inc.2007-11-14Not applicableUs
Somatuline DepotInjection90 mg/.3mLSubcutaneousIpsen Biopharmaceuticals, Inc.2007-11-14Not applicableUs
Somatuline DepotInjection90 mg/.3mLSubcutaneousIpsen Biopharmaceuticals, Inc.2007-11-14Not applicableUs
Somatuline DepotInjection120 mg/.5mLSubcutaneousIpsen Biopharmaceuticals, Inc.2007-11-14Not applicableUs
International/Other Brands
Somatuline (Ipsen)
Categories
UNII
0G3DE8943Y
CAS number
108736-35-2
Weight
Average: 1096.33
Monoisotopic: 1095.467029814
Chemical Formula
C54H69N11O10S2
InChI Key
PUDHBTGHUJUUFI-UHFFFAOYSA-N
InChI
InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)
IUPAC Name
2-({19-[2-amino-3-(naphthalen-2-yl)propanamido]-10-(4-aminobutyl)-16-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-6,9,12,15,18-pentaoxo-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}formamido)-3-hydroxybutanamide
SMILES
[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H]

Pharmacology

Indication

Lanreotide is a somatostatin analog approved for treatment of neuroendocrine tumours and acromegaly. (2)

Structured Indications
Pharmacodynamics

Lanreotide exhibits antisecretory effects through cAMP suppression, and activation of ion currents such as K+ and Ca2+ which leads to hyperpolarization of the membrane and inhibition of Ca2+ mediated depolarization. Furthermore, through direct and indirect mechanisms, Lanreotide has potent antiproliferative effects. (2)

Mechanism of action

Lanreotide is a somatostatin analogue (SSA) and has mainly inhibitory effects which are mediated via somatostatin receptors (SSTRs) 2 and 5 and include inhibition of growth hormone release in the brain. Tumor SSTR activation induces downstream cell cycle arrest and/or apoptosis, and also results in blunted production of substances that support tumor growth as well as tumor angiogenesis. This leads to the anti-proliferative effects of Lanreotide. (3)

TargetActionsOrganism
USomatostatin receptor type 2
agonist
Human
USomatostatin receptor type 5
agonist
Human
Absorption

Lanreotide forms a drug depot at the site of injection (4); therefore, there are 2 phases that describe the absorption of Lanreotide: 1. Initial rapid subcutaneous release during the first few days of treatment where drug that has not precipitated is rapidly absorbed.
2. Slow release of drug from the depot via passive diffusion. (1) Absorption is independent of body weight, gender, and dosage. (5)

Volume of distribution

Estimated Volume of Distribution = 15.1 L (1)

Protein binding
Not Available
Metabolism
Not Available
Route of elimination

<5% of lanreotide is excreted in urine, and less than 0.5% is excreted unchanged in the feces suggesting biliary excretion involvement. (4)

Half life

Half-life is approximately 22 days (5)

Clearance

Estimated Clearance = 23.1 L/h (1)

Toxicity

The most common adverse events are GI related, occurring in 67-84% of patients, and are typically mild to moderate. GI related effects are often transient, improve with subsequent injections, and most frequently include diarrhea and abdominal pain. Other GI symptoms such as nausea, vomiting, and abdominal distension are less common. It is not clear whether or not GI effects are dose related. Adverse effects relating to site of injection occur in 43% of patients and are more common in patients who self-inject as opposed to those who had health-care professionals administer the injection. A small number of patients report newly impaired glucose tolerance, fasting glucose or diabetes mellitus. Patients being treated for diabetes mellitus may experience hypoglycemia. After 1 year, up to 30% of patients may experience gallstone formation and the presence of sludge within the gallbladder due to inhibition of gallbladder and GI motility. This may be influenced by previous exposure to somatostatin analogues. Other adverse effects include reduction in left ventricular end-diastolic and end-systolic volumes, bradycardia, nasopharyngitis, and alopecia. (5) Lanreotide is classified as Pregnancy Category C. (4)

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Lanreotide.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Lanreotide.Approved, Investigational
AcebutololAcebutolol may increase the bradycardic activities of Lanreotide.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lanreotide.Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Lanreotide.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Lanreotide.Experimental
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Lanreotide.Experimental
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Lanreotide.Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Lanreotide.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Lanreotide.Approved, Investigational
AtenololAtenolol may increase the bradycardic activities of Lanreotide.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Lanreotide.Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Lanreotide.Investigational
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Lanreotide.Approved
BeractantBeractant may increase the bradycardic activities of Lanreotide.Approved
BetaxololBetaxolol may increase the bradycardic activities of Lanreotide.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Lanreotide.Approved, Investigational
BisoprololBisoprolol may increase the bradycardic activities of Lanreotide.Approved
BretyliumBretylium may increase the bradycardic activities of Lanreotide.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Lanreotide.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Lanreotide.Withdrawn
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lanreotide.Approved
CalfactantCalfactant may increase the bradycardic activities of Lanreotide.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Lanreotide.Experimental
CarteololCarteolol may increase the bradycardic activities of Lanreotide.Approved
CarvedilolCarvedilol may increase the bradycardic activities of Lanreotide.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lanreotide.Experimental
CeritinibLanreotide may increase the bradycardic activities of Ceritinib.Approved
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Lanreotide.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lanreotide.Experimental
ClonidineClonidine may increase the bradycardic activities of Lanreotide.Approved
CodeineThe metabolism of Codeine can be decreased when combined with Lanreotide.Approved, Illicit
CrizotinibLanreotide may increase the bradycardic activities of Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Lanreotide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Lanreotide.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Lanreotide.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Lanreotide.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Lanreotide.Approved
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Lanreotide.Approved, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Lanreotide.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Lanreotide.Approved
DiltiazemDiltiazem may increase the bradycardic activities of Lanreotide.Approved
DisopyramideDisopyramide may increase the hypoglycemic activities of Lanreotide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lanreotide.Approved, Investigational
DonepezilDonepezil may increase the bradycardic activities of Lanreotide.Approved
DronedaroneDronedarone may increase the bradycardic activities of Lanreotide.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lanreotide.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide.Approved
EsmololEsmolol may increase the bradycardic activities of Lanreotide.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Lanreotide.Approved, Investigational
FingolimodLanreotide may increase the bradycardic activities of Fingolimod.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Lanreotide.Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Lanreotide.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Lanreotide.Withdrawn
GliclazideGliclazide may increase the hypoglycemic activities of Lanreotide.Approved
GlimepirideGlimepiride may increase the hypoglycemic activities of Lanreotide.Approved
GlipizideGlipizide may increase the hypoglycemic activities of Lanreotide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lanreotide.Approved
GlyburideGlyburide may increase the hypoglycemic activities of Lanreotide.Approved
GuanfacineGuanfacine may increase the bradycardic activities of Lanreotide.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Lanreotide.Investigational
Insulin AspartInsulin Aspart may increase the hypoglycemic activities of Lanreotide.Approved
Insulin DetemirInsulin Detemir may increase the hypoglycemic activities of Lanreotide.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Lanreotide.Approved
Insulin GlulisineInsulin Glulisine may increase the hypoglycemic activities of Lanreotide.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Lanreotide.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Lanreotide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lanreotide.Approved
IvabradineLanreotide may increase the bradycardic activities of Ivabradine.Approved
LabetalolLabetalol may increase the bradycardic activities of Lanreotide.Approved
LacosamideLanreotide may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Lanreotide.Experimental
LevobunololLevobunolol may increase the bradycardic activities of Lanreotide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Lanreotide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Lanreotide.Approved
LucinactantLucinactant may increase the bradycardic activities of Lanreotide.Approved
MecaserminMecasermin may increase the hypoglycemic activities of Lanreotide.Approved, Investigational
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Lanreotide.Approved
MethyldopaMethyldopa may increase the bradycardic activities of Lanreotide.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Lanreotide.Experimental
MetipranololMetipranolol may increase the bradycardic activities of Lanreotide.Approved
MetoprololMetoprolol may increase the bradycardic activities of Lanreotide.Approved, Investigational
MifepristoneMifepristone may increase the hypoglycemic activities of Lanreotide.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Lanreotide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Lanreotide.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Lanreotide.Approved, Investigational
NadololNadolol may increase the bradycardic activities of Lanreotide.Approved
NateglinideNateglinide may increase the hypoglycemic activities of Lanreotide.Approved, Investigational
NebivololNebivolol may increase the bradycardic activities of Lanreotide.Approved, Investigational
OctreotideOctreotide may increase the hypoglycemic activities of Lanreotide.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Lanreotide.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Lanreotide.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lanreotide.Approved, Vet Approved
PasireotidePasireotide may increase the hypoglycemic activities of Lanreotide.Approved
PegvisomantThe risk or severity of adverse effects can be increased when Lanreotide is combined with Pegvisomant.Approved
PenbutololPenbutolol may increase the bradycardic activities of Lanreotide.Approved, Investigational
PentamidinePentamidine may increase the hypoglycemic activities of Lanreotide.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Lanreotide.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Lanreotide.Approved, Withdrawn
PindololPindolol may increase the bradycardic activities of Lanreotide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lanreotide.Approved, Investigational
Poractant alfaLanreotide may increase the bradycardic activities of Poractant alfa.Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Lanreotide.Approved, Investigational
PropafenonePropafenone may increase the bradycardic activities of Lanreotide.Approved
PropranololPropranolol may increase the bradycardic activities of Lanreotide.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Lanreotide.Experimental
QuinineQuinine may increase the hypoglycemic activities of Lanreotide.Approved
RepaglinideRepaglinide may increase the hypoglycemic activities of Lanreotide.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Lanreotide.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lanreotide.Approved, Investigational
RuxolitinibRuxolitinib may increase the bradycardic activities of Lanreotide.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lanreotide.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lanreotide.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Lanreotide.Investigational
SotalolSotalol may increase the bradycardic activities of Lanreotide.Approved
SufentanilSufentanil may increase the bradycardic activities of Lanreotide.Approved, Investigational
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Lanreotide.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the hypoglycemic activities of Lanreotide.Approved
SulfisoxazoleSulfisoxazole may increase the hypoglycemic activities of Lanreotide.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lanreotide.Approved, Investigational
SunitinibSunitinib may increase the hypoglycemic activities of Lanreotide.Approved, Investigational
TimololTimolol may increase the bradycardic activities of Lanreotide.Approved
TizanidineTizanidine may increase the bradycardic activities of Lanreotide.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Lanreotide.Approved, Investigational
TolazamideTolazamide may increase the hypoglycemic activities of Lanreotide.Approved
TolbutamideTolbutamide may increase the hypoglycemic activities of Lanreotide.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Lanreotide.Approved, Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Lanreotide.Withdrawn
VerapamilVerapamil may increase the bradycardic activities of Lanreotide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lanreotide.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Lanreotide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Troconiz IF, Cendros JM, Peraire C, Ramis J, Garrido MJ, Boscani PF, Obach R: Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months. Clin Pharmacokinet. 2009;48(1):51-62. doi: 10.2165/0003088-200948010-00004. [PubMed:19071884]
  2. Giustina A, Mazziotti G, Maffezzoni F, Amoroso V, Berruti A: Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opin Investig Drugs. 2014 Dec;23(12):1619-35. doi: 10.1517/13543784.2014.942728. Epub 2014 Jul 25. [PubMed:25060168]
  3. Narayanan S, Kunz PL: Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016 Feb;30(1):163-77. doi: 10.1016/j.hoc.2015.09.008. [PubMed:26614375]
  4. Kyriakakis N, Chau V, Lynch J, Orme SM, Murray RD: Lanreotide autogel in acromegaly - a decade on. Expert Opin Pharmacother. 2014 Dec;15(18):2681-92. doi: 10.1517/14656566.2014.970173. Epub 2014 Oct 11. [PubMed:25307803]
External Links
KEGG Drug
D04666
PubChem Compound
71349
PubChem Substance
310264887
ChemSpider
64450
ChEMBL
CHEMBL1201185
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Lanreotide
ATC Codes
H01CB03 — Lanreotide
AHFS Codes
  • 92:92.00 — Other Miscellaneous Therapeutic Agents
FDA label
Download (418 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentNeuroendocrine Tumors1
1, 2Active Not RecruitingTreatmentAcromegaly1
1, 2RecruitingTreatmentGastroenteropancreatic Neuroendocrine Tumors1
2Active Not RecruitingTreatmentCarcinoid Tumors1
2CompletedTreatmentMalignant Intestinal Obstruction1
2CompletedTreatmentNeuroendocrine Tumours1
2Not Yet RecruitingPreventionPancreatectomy; Hyperglycemia / Pancreatic Fistula / Pancreatic leak / Pancreaticoduodenal; Fistula1
2RecruitingSupportive CareIntestinal Obstruction2
2RecruitingTreatmentCarcinoid Tumors1
2RecruitingTreatmentCarcinoid Tumors / Neoplasms, Gastrointestinal / Neuroendocrine Tumors1
2RecruitingTreatmentIntestinal Diseases / Upper gastrointestinal motility disorders1
2RecruitingTreatmentNeuroendocrine Carcinoma of the Skin1
2RecruitingTreatmentNeuroendocrine Tumours1
2Unknown StatusTreatmentAcid Reflux Esophagitis / Non-acid Reflux Esophagitis1
2WithdrawnTreatmentAcromegaly1
2, 3CompletedTreatmentAcromegaly1
2, 3CompletedTreatmentAdvanced Hepatocellular Carcinoma1
2, 3CompletedTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD) / Hepatomegaly / Liver Diseases / Polycystic Liver Disease (PLD)1
2, 3CompletedTreatmentDiarrhea1
2, 3RecruitingTreatmentMetastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours1
2, 3Unknown StatusTreatmentAutosomal Dominant / Hepatomegaly / Kidney, Polycystic / Liver Diseases / Polycystic Liver Disease (PLD)1
3Active Not RecruitingTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3CompletedTreatmentAbdominal wall neoplasm / Carcinoma NOS / Intestinal Obstruction1
3CompletedTreatmentAcromegaly4
3CompletedTreatmentCarcinoid Syndrome1
3CompletedTreatmentEndocrine Tumors1
3CompletedTreatmentNon Functioning Entero-pancreatic Endocrine Tumour1
3RecruitingTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3RecruitingTreatmentNeuroendocrine Tumors1
4Active Not RecruitingTreatmentNeuroendocrine Tumors1
4CompletedDiagnosticNeuroendocrine Tumours1
4CompletedTreatmentAcromegaly2
4CompletedTreatmentNeuroendocrine Tumour With Carcinoid Symptoms1
4TerminatedTreatmentAcromegaly1
4Unknown StatusTreatmentCongenital Hyperinsulinism1
4Unknown StatusTreatmentDumping Syndrome1
Not AvailableCompletedNot AvailablePolycystic Liver Disease (PLD)1
Not AvailableNot Yet RecruitingNot AvailableAcromegaly1
Not AvailableRecruitingNot AvailableHepatocellular,Carcinoma / Neuroendocrine Tumors1
Not AvailableRecruitingTreatmentAcromegaly1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Solution, gel forming, extended releaseSubcutaneous120 mg
Solution, gel forming, extended releaseSubcutaneous60 mg
Solution, gel forming, extended releaseSubcutaneous90 mg
InjectionSubcutaneous120 mg/.5mL
InjectionSubcutaneous60 mg/.2mL
InjectionSubcutaneous90 mg/.3mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5595760No2000-03-082020-03-08Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00496 mg/mLALOGPS
logP1.87ALOGPS
logP-0.33ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)9.43ChemAxon
pKa (Strongest Basic)10.26ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area355.08 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity292.92 m3·mol-1ChemAxon
Polarizability114.68 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Oligopeptides
Alternative Parents
Cyclic peptides / N-acyl-alpha amino acids and derivatives / Macrolactams / Alpha amino acid amides / 3-alkylindoles / Naphthalenes / 1-hydroxy-2-unsubstituted benzenoids / Aralkylamines / Substituted pyrroles / Benzene and substituted derivatives
show 13 more
Substituents
Alpha-oligopeptide / Cyclic alpha peptide / Macrolactam / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / N-substituted-alpha-amino acid / Alpha-amino acid or derivatives / Naphthalene / 3-alkylindole / Indole or derivatives
show 33 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Somatostatin receptor activity
Specific Function
Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and ...
Gene Name
SSTR2
Uniprot ID
P30874
Uniprot Name
Somatostatin receptor type 2
Molecular Weight
41332.37 Da
References
  1. Buil-Bruna N, Garrido MJ, Dehez M, Manon A, Nguyen TX, Gomez-Panzani EL, Troconiz IF: Population Pharmacokinetic Analysis of Lanreotide Autogel((R))/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials. Clin Pharmacokinet. 2016 Apr;55(4):461-73. doi: 10.1007/s40262-015-0329-4. [PubMed:26416534]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Somatostatin receptor activity
Specific Function
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition act...
Gene Name
SSTR5
Uniprot ID
P35346
Uniprot Name
Somatostatin receptor type 5
Molecular Weight
39201.925 Da
References
  1. Buil-Bruna N, Garrido MJ, Dehez M, Manon A, Nguyen TX, Gomez-Panzani EL, Troconiz IF: Population Pharmacokinetic Analysis of Lanreotide Autogel((R))/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials. Clin Pharmacokinet. 2016 Apr;55(4):461-73. doi: 10.1007/s40262-015-0329-4. [PubMed:26416534]

Drug created on September 14, 2010 10:21 / Updated on October 21, 2017 19:32